Evaluating atypical antipsychotics in the treatment of refractory depression.
Treatment resistance is a common clinical occurrence among patients treated for major depressive disorder. Clinicians have several options when treating resistant depression, including switching antidepressants within the same class, switching outside the class, and augmenting with various agents, including atypical antipsychotics. Atypical antipsychotics have shown efficacy as adjuncts to antidepressants in the treatment of resistant depression, although long-term efficacy is undetermined. Atypical antipsychotics need to be compared for efficacy against specific target symptoms, as well as for differences in safety and tolerability.
Thase
Michael E
ME
Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia Veterans Affairs Medical Center, and University of Pittsburgh Medical Center, Philadelphia and Pittsburgh, PA, USA.
D000928:Antidepressive Agents / Q000378:metabolism* / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy*; D004357:Drug Synergism; D004361:Drug Tolerance; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D013997:Time Factors; D016896:Treatment Outcome
D000928:Antidepressive Agents; D014150:Antipsychotic Agents